Meropenem monotherapy for the treatment of hospital-acquired pneumonia

Results of a multicenter trial

S. J. Berman, C. M. Fogarty, Timothy Fabian, D. Melnick, W. Lesky

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The efficacy and tolerability of meropenem as empirical treatment in patients with hospital-acquired pneumonia was determined in a prospective, open-label, non-randomized trial. Patients from 28 centers in the USA received meropenem 1 g every 8 h intravenously. Of 255 patients enrolled, 111 were evaluable for efficacy, including 60 patients with ventilator-associated pneumonia. At end of treatment 74% of patients had a satisfactory clinical response and 64% had this response at follow-up, which could last up to 28 days after treatment. In patients with ventilator-associated pneumonia, a satisfactory clinical response was observed in 63% at the end of treatment and 63% at follow-up. The overall satisfactory response rate for individual pretreatment pathogens ranged from 65% to 100%. This study demonstrates that meropenem monotherapy is effective and well tolerated for patients with hospital-acquired pneumonia, including a subgroup of patients with ventilator-associated pneumonia.

Original languageEnglish (US)
Pages (from-to)362-371
Number of pages10
JournalJournal of Chemotherapy
Volume16
Issue number4
DOIs
StatePublished - Jan 1 2004

Fingerprint

meropenem
Multicenter Studies
Pneumonia
Ventilator-Associated Pneumonia
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Meropenem monotherapy for the treatment of hospital-acquired pneumonia : Results of a multicenter trial. / Berman, S. J.; Fogarty, C. M.; Fabian, Timothy; Melnick, D.; Lesky, W.

In: Journal of Chemotherapy, Vol. 16, No. 4, 01.01.2004, p. 362-371.

Research output: Contribution to journalArticle

Berman, S. J. ; Fogarty, C. M. ; Fabian, Timothy ; Melnick, D. ; Lesky, W. / Meropenem monotherapy for the treatment of hospital-acquired pneumonia : Results of a multicenter trial. In: Journal of Chemotherapy. 2004 ; Vol. 16, No. 4. pp. 362-371.
@article{904ec565894d465eb0e765f62cb84856,
title = "Meropenem monotherapy for the treatment of hospital-acquired pneumonia: Results of a multicenter trial",
abstract = "The efficacy and tolerability of meropenem as empirical treatment in patients with hospital-acquired pneumonia was determined in a prospective, open-label, non-randomized trial. Patients from 28 centers in the USA received meropenem 1 g every 8 h intravenously. Of 255 patients enrolled, 111 were evaluable for efficacy, including 60 patients with ventilator-associated pneumonia. At end of treatment 74{\%} of patients had a satisfactory clinical response and 64{\%} had this response at follow-up, which could last up to 28 days after treatment. In patients with ventilator-associated pneumonia, a satisfactory clinical response was observed in 63{\%} at the end of treatment and 63{\%} at follow-up. The overall satisfactory response rate for individual pretreatment pathogens ranged from 65{\%} to 100{\%}. This study demonstrates that meropenem monotherapy is effective and well tolerated for patients with hospital-acquired pneumonia, including a subgroup of patients with ventilator-associated pneumonia.",
author = "Berman, {S. J.} and Fogarty, {C. M.} and Timothy Fabian and D. Melnick and W. Lesky",
year = "2004",
month = "1",
day = "1",
doi = "10.1179/joc.2004.16.4.362",
language = "English (US)",
volume = "16",
pages = "362--371",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Meropenem monotherapy for the treatment of hospital-acquired pneumonia

T2 - Results of a multicenter trial

AU - Berman, S. J.

AU - Fogarty, C. M.

AU - Fabian, Timothy

AU - Melnick, D.

AU - Lesky, W.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - The efficacy and tolerability of meropenem as empirical treatment in patients with hospital-acquired pneumonia was determined in a prospective, open-label, non-randomized trial. Patients from 28 centers in the USA received meropenem 1 g every 8 h intravenously. Of 255 patients enrolled, 111 were evaluable for efficacy, including 60 patients with ventilator-associated pneumonia. At end of treatment 74% of patients had a satisfactory clinical response and 64% had this response at follow-up, which could last up to 28 days after treatment. In patients with ventilator-associated pneumonia, a satisfactory clinical response was observed in 63% at the end of treatment and 63% at follow-up. The overall satisfactory response rate for individual pretreatment pathogens ranged from 65% to 100%. This study demonstrates that meropenem monotherapy is effective and well tolerated for patients with hospital-acquired pneumonia, including a subgroup of patients with ventilator-associated pneumonia.

AB - The efficacy and tolerability of meropenem as empirical treatment in patients with hospital-acquired pneumonia was determined in a prospective, open-label, non-randomized trial. Patients from 28 centers in the USA received meropenem 1 g every 8 h intravenously. Of 255 patients enrolled, 111 were evaluable for efficacy, including 60 patients with ventilator-associated pneumonia. At end of treatment 74% of patients had a satisfactory clinical response and 64% had this response at follow-up, which could last up to 28 days after treatment. In patients with ventilator-associated pneumonia, a satisfactory clinical response was observed in 63% at the end of treatment and 63% at follow-up. The overall satisfactory response rate for individual pretreatment pathogens ranged from 65% to 100%. This study demonstrates that meropenem monotherapy is effective and well tolerated for patients with hospital-acquired pneumonia, including a subgroup of patients with ventilator-associated pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=3943062850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3943062850&partnerID=8YFLogxK

U2 - 10.1179/joc.2004.16.4.362

DO - 10.1179/joc.2004.16.4.362

M3 - Article

VL - 16

SP - 362

EP - 371

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -